1/12
08:05 am
wve
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]
Low
Report
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]
1/12
07:30 am
wve
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Low
Report
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
1/11
01:03 am
wve
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
Low
Report
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
1/5
08:30 am
wve
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
1/3
01:08 am
wve
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
1/2
10:56 am
wve
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target [Yahoo! Finance]
1/1
07:15 am
wve
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) [Yahoo! Finance]
Medium
Report
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) [Yahoo! Finance]
12/31
11:30 am
wve
Wave Life Sciences' (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss [Yahoo! Finance]
Low
Report
Wave Life Sciences' (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss [Yahoo! Finance]
12/25
01:46 am
wve
What New Catalysts Are Rewriting the Narrative for Wave Life Sciences? [Yahoo! Finance]
Medium
Report
What New Catalysts Are Rewriting the Narrative for Wave Life Sciences? [Yahoo! Finance]
12/19
11:05 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/16
09:11 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $32.00 price target on by analysts at UBS Group AG.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $32.00 price target on by analysts at UBS Group AG.
12/16
08:04 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/15
09:11 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $50.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $50.00 price target on by analysts at Truist Financial Corporation.
12/14
02:47 pm
wve
Wave Life (WVE) Shares Nearly Triple on Encouraging Obesity Drug Trial [Yahoo! Finance]
Medium
Report
Wave Life (WVE) Shares Nearly Triple on Encouraging Obesity Drug Trial [Yahoo! Finance]
12/13
01:10 am
wve
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
12/12
09:12 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.
12/12
07:12 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Wedbush.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "outperform" rating reaffirmed by analysts at Wedbush.
12/10
07:39 am
wve
Wave Life Sciences: 200% Rally On 1% Weight Loss Feels Bloated [Seeking Alpha]
Low
Report
Wave Life Sciences: 200% Rally On 1% Weight Loss Feels Bloated [Seeking Alpha]
12/10
01:56 am
wve
Wave Life Science prices upsized $350M stock ofeering [Seeking Alpha]
Medium
Report
Wave Life Science prices upsized $350M stock ofeering [Seeking Alpha]
12/9
11:18 pm
wve
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
12/9
09:50 pm
wve
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Medium
Report
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
12/9
08:53 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an "overweight" rating on the stock.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an "overweight" rating on the stock.
12/9
08:44 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $30.00 price target on by analysts at UBS Group AG.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $30.00 price target on by analysts at UBS Group AG.
12/9
07:21 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/9
07:21 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.